Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06170788 · ClinicalTrials.gov registry record · Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

A Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 3
Development phase
614
Enrollment target
20
Study locations

NCT06170788: Recruiting Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Merck Sharp & Dohme.

NCT06170788 is a Phase 3 study of Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 614 participants, above the 275-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 19 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06170788, a Phase 3 study of Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 3
Development phase
614 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.

Primary Outcome

OS is defined as the time from randomization to death from any cause.

Conditions Studied

Non-small Cell Lung Cancer (NSCLC)

Interventions

  • BIOLOGICAL Sacituzumab tirumotecan
  • BIOLOGICAL Pembrolizumab
  • DRUG Supportive care measures

Study Locations (20)

Minnesota

  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115) - Minneapolis
  • Mayo Clinic - Rochester ( Site 0148) - Rochester

Arizona

  • Mayo Clinic in Arizona - Phoenix ( Site 0147) - Phoenix

California

  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) - Burbank

Colorado

  • Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) - Grand Junction

Florida

  • Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) - Jacksonville

Georgia

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106) - Marietta

Kentucky

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0121) - Louisville

Maine

  • New England Cancer Specialists ( Site 0143) - Westbrook

Trial Details

FieldValue
Enrollment Target 614 participants
Start Date 2023-12-15
Est. Completion 2030-05-27
Phase Phase 3
Merck Sharp & Dohme

558 total trials

What NCT06170788 shows while recruiting

NCT06170788 is an interventional study that assigns participants to a tested intervention. The registered 614 participants enrollment target is mid-sized for trials with a published cap, above the 275-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (123% higher).

The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 3 interventions - of which Sacituzumab tirumotecan is the first listed.

NCT06170788 names 20 study sites across 19 states, led by Minnesota, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06170788 about?

NCT06170788 is a clinical study titled "Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)". The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respe...

What is the current status of trial NCT06170788?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2023-12-15. Estimated completion is 2030-05-27.

What conditions does trial NCT06170788 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT06170788?

The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Pembrolizumab (BIOLOGICAL), Supportive care measures (DRUG).

Who is sponsoring clinical trial NCT06170788?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06170788 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06170788's enrollment target sits among peer trials

614 8th of 59 higher than 52 of 59 other Non-small Cell Lung Cancer (NSCLC) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03821857 · 614 participants · Phase 4

    Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

  • NCT05006716 · 614 participants · Phase 1

    A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

  • NCT07409272 · 614 participants · Phase 3

    A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  • NCT06593652 · 615 participants · NA

    Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06170788

Source: ClinicalTrials.gov NCT06170788, the US trial registry maintained by the National Library of Medicine. NCT06170788 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.